396 related articles for article (PubMed ID: 35493518)
1. Development and Validation of TACE Refractoriness-Related Diagnostic and Prognostic Scores and Characterization of Tumor Microenvironment Infiltration in Hepatocellular Carcinoma.
He Q; Yang J; Jin Y
Front Immunol; 2022; 13():869993. PubMed ID: 35493518
[TBL] [Abstract][Full Text] [Related]
2. A novel prognostic signature based on immunogenic cell death score predicts outcomes and response to transcatheter arterial chemoembolization and immunotherapy in hepatocellular carcinoma.
Zhang Y; Yang J; Xie S; Chen H; Zhong J; Lin X; Yu Z; Xia J
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11411-11429. PubMed ID: 37382674
[TBL] [Abstract][Full Text] [Related]
3. Construction and validation of an angiogenesis-related scoring model to predict prognosis, tumor immune microenvironment and therapeutic response in hepatocellular carcinoma.
Tang B; Zhang X; Yang X; Wang W; Li R; Liu Y
Front Immunol; 2022; 13():1013248. PubMed ID: 36466855
[TBL] [Abstract][Full Text] [Related]
4. Overweight/obesity-related transcriptomic signature as a correlate of clinical outcome, immune microenvironment, and treatment response in hepatocellular carcinoma.
Feng NN; Du XY; Zhang YS; Jiao ZK; Wu XH; Yang BM
Front Endocrinol (Lausanne); 2022; 13():1061091. PubMed ID: 36714595
[TBL] [Abstract][Full Text] [Related]
5. Development of a computed tomography-based radiomics nomogram for prediction of transarterial chemoembolization refractoriness in hepatocellular carcinoma.
Niu XK; He XF
World J Gastroenterol; 2021 Jan; 27(2):189-207. PubMed ID: 33510559
[TBL] [Abstract][Full Text] [Related]
6. Mitochondrial-Related Transcriptome Feature Correlates with Prognosis, Vascular Invasion, Tumor Microenvironment, and Treatment Response in Hepatocellular Carcinoma.
Wang Y; Song F; Zhang X; Yang C
Oxid Med Cell Longev; 2022; 2022():1592905. PubMed ID: 35535359
[TBL] [Abstract][Full Text] [Related]
7. Prognostic nomogram for post-surgical treatment with adjuvant TACE in hepatitis B virus-related hepatocellular carcinoma.
Hu H; Han XK; Long XR; Fan J; Yan ZP; Wang JH; Liu R
Oncotarget; 2016 Sep; 7(36):58302-58314. PubMed ID: 27506942
[TBL] [Abstract][Full Text] [Related]
8. Immune-related gene signature to predict TACE refractoriness in patients with hepatocellular carcinoma based on artificial neural network.
Xu Q; Wang C; Yin G
Front Genet; 2022; 13():993509. PubMed ID: 36685822
[No Abstract] [Full Text] [Related]
9. Identification and characterization of a novel molecular classification based on disulfidptosis-related genes to predict prognosis and immunotherapy efficacy in hepatocellular carcinoma.
Yang L; Zhang W; Yan Y
Aging (Albany NY); 2023 Jul; 15(13):6135-6151. PubMed ID: 37399661
[TBL] [Abstract][Full Text] [Related]
10. A radiomics nomogram for predicting transcatheter arterial chemoembolization refractoriness of hepatocellular carcinoma without extrahepatic metastasis or macrovascular invasion.
Sheen H; Kim JS; Lee JK; Choi SY; Baek SY; Kim JY
Abdom Radiol (NY); 2021 Jun; 46(6):2839-2849. PubMed ID: 33388805
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors and an innovative nomogram model for patients with hepatocellular carcinoma treated with postoperative adjuvant transarterial chemoembolization.
Xu JX; Qin SL; Wei HW; Chen YY; Peng YC; Qi LN
Ann Med; 2023 Dec; 55(1):2199219. PubMed ID: 37070467
[TBL] [Abstract][Full Text] [Related]
12. Risk Factors for Liver Function Deterioration after Transarterial Chemoembolization Refractoriness in Child-Pugh Class A Hepatocellular Carcinoma Patients.
Park KH; Kim JH; Choe WH; Kwon SY; Yoo BC; Hwang JH; Park SW; Kim YJ; Park HS; Yu MH; Jeon HJ
Korean J Gastroenterol; 2020 Mar; 75(3):147-156. PubMed ID: 32209803
[TBL] [Abstract][Full Text] [Related]
13. Construction and validation of a novel lysosomal signature for hepatocellular carcinoma prognosis, diagnosis, and therapeutic decision-making.
Chen J; Gao G; He Y; Zhang Y; Wu H; Dai P; Zheng Q; Huang H; Weng J; Zheng Y; Huang Y
Sci Rep; 2023 Dec; 13(1):22624. PubMed ID: 38114725
[TBL] [Abstract][Full Text] [Related]
14. Identification of PANoptosis-Based Prognostic Signature for Predicting Efficacy of Immunotherapy and Chemotherapy in Hepatocellular Carcinoma.
Xiong X; Song Q; Jing M; Yan W
Genet Res (Camb); 2023; 2023():6879022. PubMed ID: 37313428
[TBL] [Abstract][Full Text] [Related]
15. Idarubicin-loaded biodegradable microspheres enhance sensitivity to anti-PD1 immunotherapy in transcatheter arterial chemoembolization of hepatocellular carcinoma.
Zheng Z; Ma M; Han X; Li X; Huang J; Zhao Y; Liu H; Kang J; Kong X; Sun G; Sun G; Kong J; Tang W; Shao G; Xiong F; Song J
Acta Biomater; 2023 Feb; 157():337-351. PubMed ID: 36509402
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Value of TP53 Mutation for Transcatheter Arterial Chemoembolization Failure/Refractoriness in HBV-Related Advanced Hepatocellular Carcinoma.
Xue M; Wu Y; Fan W; Guo J; Wei J; Wang H; Tan J; Wang Y; Yao W; Zhao Y; Li J
Cancer Res Treat; 2020 Jul; 52(3):925-937. PubMed ID: 32229792
[TBL] [Abstract][Full Text] [Related]
17. Prognostic nomogram for hepatocellular carcinoma patients after transarterial chemoembolization based on des-γ-carboxy prothrombin reactivity and modified Response Evaluation Criteria in Solid Tumors.
Zhao SM; Qiu LW; Zhao H; Gu WW; Yang XH; Gu ZX; Shi RF; Ni CF
J Cancer Res Ther; 2021 Jul; 17(3):707-714. PubMed ID: 34269303
[TBL] [Abstract][Full Text] [Related]
18. Validation of the six-and-twelve criteria among patients with hepatocellular carcinoma and performance score 1 receiving transarterial chemoembolization.
Wang ZX; Li J; Wang EX; Xia DD; Bai W; Wang QH; Yuan J; Li XM; Niu J; Yin ZX; Xia JL; Fan DM; Han GH
World J Gastroenterol; 2020 Apr; 26(15):1805-1819. PubMed ID: 32351295
[TBL] [Abstract][Full Text] [Related]
19. The Clinical Impact of Transcatheter Arterial Chemoembolization (TACE)-Induced c-Met Upregulation on TACE Refractoriness in Hepatocellular Carcinoma.
Kajihara J; Tomimaru Y; Eguchi H; Yamada D; Wada H; Tomokuni A; Asaoka T; Kawamoto K; Marubashi S; Nagano H; Umeshita K; Doki Y; Mori M
Dig Dis Sci; 2016 Jun; 61(6):1572-81. PubMed ID: 26725068
[TBL] [Abstract][Full Text] [Related]
20. Transarterial chemoembolization combined with recombinant human adenovirus type 5 H101 prolongs overall survival of patients with intermediate to advanced hepatocellular carcinoma: a prognostic nomogram study.
He CB; Lao XM; Lin XJ
Chin J Cancer; 2017 Jul; 36(1):59. PubMed ID: 28728568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
